Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. A confirmed diagnosis of IMO with documented TCIRG1 mutation.~2. Age at least 1 month with minimum weight of 4 kg~3. Absence of debilitating hydrocephalus (defined as hydrocephalus at NCI CTCAE v5.0 Grade 3 or higher persisting despite shunt or similar procedural intervention).~4. Lansky Play Scale of at least 60%~5. Preserved hepatic function (AST/ALT ≤3.0 ULN; bilirubin ≤1.5 ULN; to minimize potential for excessive toxicity from busulfan conditioning)~6. No concomitant medical or other conditions that would represent a contraindication to autologous hematopoietic stem cell transplant.~7. Absolute neutrophil count of ≥500/mm3 and platelet count of ≥25,000/mm3~8. No prior allogeneic or other hematopoietic stem cell transplant.~9. Availability of a non-autologous rescue (back-up) hematopoietic stem cell donor/source~Exclusion Criteria:~1. Availability of medically-feasible HLA-matched sibling donor for allogeneic HSCT.~2. Any medical or other contraindication for either apheresis or autologous transplant as determined by the Investigator.~3. Participation in another clinical trial with an investigational drug within 14 days before the informed consent signature. Participation in observational studies is allowed.~4. Active hematologic or solid organ malignancy, not including non-melanoma skin cancer or another carcinoma in situ.~5. Uncontrolled seizure disorder.~6. Renal dysfunction as defined by a glomerular filtration rate \<30 mL/min/1.73m2 or dialysis dependence.~7. Serious infections with persistent bloodstream pathogens at time of trial entry~8. Pulmonary dysfunction as defined by either:~   * Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection) or~  * Oxygen saturation (by pulse oximetry) \<90% resulting from pulmonary conditions (intermittent hypoxia secondary to IMO-related choanal atresia will not be considered exclusionary)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental - RP-L401 (Type: EXPERIMENTAL): RP-L401 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with lentiviral vector carrying the TCIRG1 transgene

Based on this trial design, predict the completion outcome and termination type (if applicable).